A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non Endemic Chikungunya Region
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2017
At a glance
- Drugs MRNA 1388 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions; First in man
- Sponsors Moderna Therapeutics
- 14 Sep 2017 According to a Moderna Therapeutics media release, this trial is supported by Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense.
- 14 Sep 2017 Status changed from planning to recruiting, according to a Moderna Therapeutics media release.
- 13 Jan 2017 New trial record